This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 2 of 566

Puma Shares Soar When Wall Street Misplays Expectation Game

By Adam Feuerstein

Puma is why so many investors love to speculate on biotech stocks. A contrarian trade against a heavily expected outcome can return a fortune.

12:26PM 07/23/14

Inovio Declares Spin-Laden Victory With DNA Vaccine

By Adam Feuerstein

Inovio's analysis of the VGX-3100 study omits an unknown number of patients, calling the results into question.

10:17AM 07/23/14

Gilead Expected to Post Sky-High Hep C Sales in June Quarter

By Adam Feuerstein

The buyside "whisper number" for Sovaldi sales is $3.5 billion. But everyone who follows Gilead knows this, which means the "whispered" whisper number for sales is $4 billion or more.

12:12PM 07/22/14

Galena Gives Sales Team Another Useless Product to Promote

By Adam Feuerstein

Galena stands little chance of delivering higher sales of Zuplenz than its previous marketer.

09:41AM 07/22/14

Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

07:51AM 07/18/14

Fed Chair Yellen Says Small Biotech Stocks Over-Valued

By Adam Feuerstein

Biotech indices plunge on cautious remarks made by Fed Chairwoman during Congressional testimony.

01:10PM 07/15/14

Investor Believes Roche Buys Exelixis for Skin-Cancer Drug

By Adam Feuerstein

Healthcare investor David Miller believes Roche will likely acquire Exelixis in order to capture the full economics of the cancer drug cobimetinib.

11:14AM 07/14/14

Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

09:30AM 07/14/14

Roche, Exelixis Skin Cancer Drug Delays Tumor Progression

By Adam Feuerstein

Roche intends to seek U.S. approval for cobimetinib later this year.

07:46AM 07/14/14

14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014

By Adam Feuerstein

Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.

11:54AM 07/10/14

Page 2 of 566

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs